- Home
- KALV vs SSTK Comparison
KALV vs SSTK Comparison
Compare KALV & SSTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- SSTK
- Stock Information
- Founded
- KALV N/A
- SSTK 2003
- Country
- KALV United States
- SSTK United States
- Employees
- KALV N/A
- SSTK N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- SSTK EDP Services
- Sector
- KALV Health Care
- SSTK Technology
- Exchange
- KALV Nasdaq
- SSTK Nasdaq
- Market Cap
- KALV 637.9M
- SSTK 668.4M
- IPO Year
- KALV N/A
- SSTK 2012
- Fundamental
- Price
- KALV $12.34
- SSTK $19.54
- Analyst Decision
- KALV Strong Buy
- SSTK Buy
- Analyst Count
- KALV 9
- SSTK 4
- Target Price
- KALV $26.29
- SSTK $43.67
- AVG Volume (30 Days)
- KALV 1.0M
- SSTK 315.3K
- Earning Date
- KALV 09-04-2025
- SSTK 07-29-2025
- Dividend Yield
- KALV N/A
- SSTK 6.57%
- EPS Growth
- KALV N/A
- SSTK 38.48
- EPS
- KALV N/A
- SSTK 1.81
- Revenue
- KALV N/A
- SSTK $1,010,504,000.00
- Revenue This Year
- KALV N/A
- SSTK $10.45
- Revenue Next Year
- KALV $192.67
- SSTK $3.19
- P/E Ratio
- KALV N/A
- SSTK $11.07
- Revenue Growth
- KALV N/A
- SSTK 14.20
- 52 Week Low
- KALV $7.30
- SSTK $14.35
- 52 Week High
- KALV $16.32
- SSTK $38.80
- Technical
- Relative Strength Index (RSI)
- KALV 36.00
- SSTK 53.00
- Support Level
- KALV $12.19
- SSTK $19.89
- Resistance Level
- KALV $14.35
- SSTK $22.00
- Average True Range (ATR)
- KALV 0.61
- SSTK 0.97
- MACD
- KALV -0.30
- SSTK 0.04
- Stochastic Oscillator
- KALV 5.26
- SSTK 46.69
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About SSTK Shutterstock Inc.
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.